The COVAIL trial reveals that neutralizing antibody titers correlate with COVID-19 risk reduction after mRNA boosters. Learn how this impacts vaccine strategies against emerging variants.

Certain antiviral and mAb therapies were shown to lower mortality and hospitalization rates in those infected with SARS-CoV-2 Omicron variants.

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their ...

GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. GSK’s Beat-and-Raise Results ...

Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current ...

The first recipient of a gene-edited pig kidney died from cardiac causes 52 days after xenotransplantation. The world's first ...

Blue Trust Inc. grew its holdings in Genmab A/S (NASDAQ:GMAB – Free Report) by 33.4% during the fourth quarter, ...

Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...

Introduction: A limited subset of HIV-1 infected adult individuals typically after at least 2-3 years of chronic infection ... at the age of 9 years and were followed for a total period of 60 months.

Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 13.6% during the 4th quarter, according to the company in its most ...

A newly developed vaccine against a group of viruses including SARS-CoV-2 is producing promising results in mice, part of the ...

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for ...